MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Aptose Biosciences Company Profile (NASDAQ:APTO)

Consensus Ratings for Aptose Biosciences (NASDAQ:APTO) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $13.75 (495.24% upside)

Analysts' Ratings History for Aptose Biosciences (NASDAQ:APTO)
Show:
DateFirmActionRatingPrice TargetActions
6/25/2016RBC CapitalReiterated RatingOutperform$23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016Roth CapitalUpgradeNeutral -> Buy$4.00 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016Canaccord GenuityReiterated RatingBuy$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016OppenheimerReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Aptose Biosciences (NASDAQ:APTO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
3/29/2016Q415($0.28)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q315($0.33)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215($0.36)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/4/2015($0.31)($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Aptose Biosciences (NASDAQ:APTO)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.30)($0.29)($0.30)
Q2 20162($0.31)($0.31)($0.31)
Q3 20162($0.32)($0.24)($0.28)
Q4 20162($0.34)($0.26)($0.30)
(Data provided by Zacks Investment Research)
Dividend History for Aptose Biosciences (NASDAQ:APTO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Aptose Biosciences (NASDAQ:APTO)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Aptose Biosciences (NASDAQ:APTO)
DateHeadline
06/22/16 07:19 AMAptose Biosciences Announces Results of Annual Meeting of Shareholders - GlobeNewswire (press release)
06/21/16 03:19 PMAptose Biosciences Announces Results of Annual Meeting of Shareholders - [at noodls] - SAN DIEGO and TORONTO, June 21, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) ('Aptose' or the 'Company') today announced the voting results from the Company's annual meeting ...
06/21/16 02:29 PMAptose Biosciences Provides Corporate Update in Advance of Annual Meeting of Shareholders - GlobeNewswire (press release)
06/21/16 02:29 PMForm 6-K Aptose Biosciences Inc. For: Jun 21 - StreetInsider.com
06/21/16 07:18 AMAptose Biosciences Provides Corporate Update in Advance of Annual Meeting of Shareholders - Nasdaq
06/21/16 07:00 AMAptose Biosciences Provides Corporate Update in Advance of Annual Meeting of Shareholders - [GlobeNewswire] - SAN DIEGO and TORONTO, June 21, 2016-- Aptose Biosciences Inc. today provided a corporate update in advance of the Company’ s Annual General Meeting of shareholders to be held today at 10:00 AM ET in Toronto, ...
06/19/16 07:17 AMAptose Biosciences, Inc. (APTO) Analyst Price Targets For The Coming Week - Fiscal Standard
06/13/16 02:43 PMAptose Upgraded To Buy At Roth, Price Target Doubled
06/13/16 10:37 AMAPTO-253
06/13/16 10:37 AM6 Largest Price Target Changes For Monday
06/13/16 05:16 AMAptose Biosciences upgraded by ROTH Capital -
06/11/16 10:44 AMAptose, CrystalGenomics ink global option & license pact for non-covalent BTK/ FLT3/AURK inhibitor
06/08/16 11:00 AMAptose Biosciences and CrystalGenomics Announce Exclusive Agreement for Non-Covalent BTK / FLT3 / AURK Inhibitor - GlobeNewswire (press release)
06/08/16 11:00 AMBRIEF-Aptose Biosciences, CrystalGenomics sign cancer drug deal - Reuters
06/08/16 07:18 AMAptose Biosciences and CrystalGenomics Announce Exclusive Agreement for Non-Covalent BTK / FLT3 / AURK Inhibitor - [at noodls] - TORONTO and SEOUL, South Korea, June 08, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) and CrystalGenomics, Inc. (KOSDAQ:083790) today announced an exclusive global option and ...
06/08/16 07:15 AM8:15 am Aptose Biosciences and CrystalGenomics announce exclusive global option and license agreement focused on the development of CG026806 -
06/01/16 10:57 AMAptose Biosciences, Inc. (NASDAQ:APTO) Stock Update & Estimates - Stock Tick Tock - Aptose Biosciences, Inc. (NASDAQ:APTO) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Aptose Biosciences, Inc. (NASDAQ:APTO) to post earnings of $-0.3 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be ...and more »
06/01/16 10:57 AMBuy, Sell Or Hold Rating For Aptose Biosciences, Inc. (APTO)? - Share Trading News - Buy, Sell Or Hold Rating For Aptose Biosciences, Inc. (APTO)?Share Trading News03/30/2016 – Aptose Biosciences, Inc. had its “outperform” rating reiterated by analysts at RBC Capital. They now have a USD 18 price target on the stock. 11/23/2015 – Aptose Biosciences, Inc. had its “outperform” rating reiterated by analysts at ...
05/26/16 10:46 AMLatest Analyst Ratings For Aptose Biosciences, Inc. (APTO) - Share Trading News - Latest Analyst Ratings For Aptose Biosciences, Inc. (APTO)Share Trading News03/30/2016 – Aptose Biosciences, Inc. had its “outperform” rating reiterated by analysts at RBC Capital. They now have a USD 18 price target on the stock. 11/23/2015 – Aptose Biosciences, Inc. had its “outperform” rating reiterated by analysts at ...
03/14/16 07:00 AMAptose To Release Fourth Quarter and Year End December 31, 2015 Financial Results and Hold Conference Call on March 29, 2016 - [GlobeNewswire] - SAN DIEGO and TORONTO, March 14, 2016-- Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, will release ...
03/03/16 04:00 PMAptose to Participate in Upcoming Investor Conferences - [GlobeNewswire] - SAN DIEGO and TORONTO, March 03, 2016-- Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced ...
02/18/16 04:00 PMAptose to Present at the 2016 RBC Capital Markets Global Healthcare Conference - [GlobeNewswire] - SAN DIEGO and TORONTO, Feb. 18, 2016-- Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced ...
02/14/16 01:30 PMAptose Biosciences Incorporated (NASDAQ:APTO) Shorted Shares Increased 4.99% After Market Selling - fdanewsalert.com - Aptose Biosciences Incorporated (NASDAQ:APTO) Shorted Shares Increased 4.99% After Market Sellingfdanewsalert.comThe short interest to Aptose Biosciences Incorporated's float is 0.48%. The stock is down 1.24% or $0.03 after the news, hitting $2.39 per share. About 655 shares traded hands. Aptose Biosciences Inc (NASDAQ:APTO) has declined 48.62% since July 9, 2015 ...and more »
02/07/16 01:06 PMAptose Biosciences Incorporated (NASDAQ:APTO) Shorted Shares Increased 21.15% After Market Selling - fdanewsalert.com - Aptose Biosciences Incorporated (NASDAQ:APTO) Shorted Shares Increased 21.15% After Market Sellingfdanewsalert.comThe short interest to Aptose Biosciences Incorporated's float is 0.46%. The stock is down 9.46% or $0.28 after the news, hitting $2.68 per share. About 21,615 shares traded hands or 61.54% up from the average. Aptose Biosciences Inc (NASDAQ:APTO) has ...and more »
02/03/16 01:02 PMIt Seems Aptose Biosciences Inc Will Go Up. Have Another Big Increase - WallStreet.org - It Seems Aptose Biosciences Inc Will Go Up. Have Another Big IncreaseWallStreet.orgAptose Biosciences Inc. is a clinical stage biotechnology company. The company has a market cap of $48.79 million. The Firm is engaged in development of targeted therapies addressing unmet medical needs in oncology. It currently has negative earnings.
01/27/16 12:20 PMSentiment And Earnings Update For Aptose Biosciences, Inc. (NASDAQ:APTO) - Investor Newswire - Sentiment And Earnings Update For Aptose Biosciences, Inc. (NASDAQ:APTO)Investor NewswireZacks Research aggregated analysts opinion on Aptose Biosciences, Inc. (NASDAQ:APTO) and assigned an average broker rating of 2. The research company rating methodology takes into account the research brokerage firms' forecasts on a scale of one to ...and more »
01/22/16 06:59 PMWhy Aptose Biosciences, Inc. (NASDAQ:APTO) Stock Is In The Spotlight? - Stocks Daily - Why Aptose Biosciences, Inc. (NASDAQ:APTO) Stock Is In The Spotlight?Stocks DailyAptose Biosciences, Inc. (NASDAQ:APTO) have been getting positive report from the sell-side analysts. Zacks published the results of recently conducted poll wherein the company cherished a mean rating of 2 rating. To make it clearer, this number is ...and more »
01/20/16 11:57 AMCytoDyn Appoints Denis R. Burger, Ph.D., as Chief Science Officer - CNNMoney - CytoDyn Appoints Denis R. Burger, Ph.D., as Chief Science OfficerCNNMoneyDr. Burger is currently lead director of Aptose Biosciences Inc., a cancer therapeutics, NASDAQ-listed company. Dr. Burger co-founded Trinity Biotech, a NASDAQ-listed diagnostic company, in June 1992, served as its Chairman from June 1992 to May 1995, ...and more »
01/20/16 11:57 AMCytoDyn Appoints Denis R. Burger, Ph.D., As Chief Science Officer - Dr. Burger is currently lead director of Aptose Biosciences Inc., a cancer therapeutics, NASDAQ-listed company. Dr. Burger co-founded Trinity Biotech, a NASDAQ-listed diagnostic company, in June 1992, served as its Chairman from June 1992 to May 1995 ...
01/19/16 06:41 PMAnalysts Issue Earnings Forecast For Aptose Biosciences, Inc. (NASDAQ:APTO) - Investor Newswire - Analysts Issue Earnings Forecast For Aptose Biosciences, Inc. (NASDAQ:APTO)Investor NewswireAccording to analysts surveyed by Zacks Research, Aptose Biosciences, Inc. (NASDAQ:APTO) is expected to post earnings of $-0.22 per share for its most recent quarter. The company is set to release its earnings around 2016-03-01. Since the same set of ...and more »
12/08/15 12:06 PMAPTOSE BIOSCIENCES INC. Financials -
12/03/15 07:00 AMMoffitt Cancer Center and Aptose Biosciences to Present Data on a Novel Class of Dual-Targeting Bromodomain / Kinase Inhibitors at 57th Annual American Society of Hematology (ASH) Meeting - [GlobeNewswire] - REDWOOD CITY, Calif., TORONTO and TAMPA, Fla. -- Aptose Biosciences Inc. (NASDAQ:APTO) today announced that its collaborator, Moffitt Cancer Center, will present preclinical data for its dual-targeting ...
11/30/15 04:00 PMAptose Biosciences to Participate in Upcoming Investor Conferences - [GlobeNewswire] - SAN DIEGO and TORONTO -- Aptose Biosciences Inc. (NASDAQ:APTO) , a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced ...
11/30/15 09:44 AMShould You Buy Aptose Biosciences Inc (APTO)? -
11/23/15 12:13 PM[$$] Aptose's Cancer Drug to Overcome Issues -
11/20/15 06:30 AMAptose Voluntarily Suspends Clinical Dosing of APTO-253 to Review Drug Manufacturing Processes and Procedures - [GlobeNewswire] - SAN DIEGO, California and TORONTO, Ontario -- Aptose Biosciences Inc. (NASDAQ:APTO) (Aptose or the Company), a clinical-stage company developing new therapeutics and molecular diagnostics that target the ...
11/10/15 03:16 PMAptose Biosciences reports 3Q loss -
11/10/15 03:05 PMAptose Biosciences Reports Results for the Third Quarter Ended September 30, 2015 - [GlobeNewswire] - SAN DIEGO and TORONTO -- Aptose Biosciences Inc. (NASDAQ:APTO) a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today reported ...
11/10/15 07:30 AMAptose Biosciences Announces Collaborations for New Multi-Targeting Epigenetic Therapeutic Agents - [GlobeNewswire] - Moffitt Cancer Center Grants Aptose Exclusive Global Rights to Highly Potent Multi-Targeting Epigenetic Inhibitors
11/05/15 08:15 AMBeat AML & Aptose Biosciences Present Data for APTO-253 at the 57th American Society of Hematology (ASH) Annual Meeting - [GlobeNewswire] - SAN DIEGO and TORONTO -- Aptose Biosciences Inc. (NASDAQ:APTO) , a clinical-stage company developing targeted agents and molecular diagnostics to treat the underlying mechanisms of cancer, today announced ...
11/05/15 07:00 AMAptose Biosciences to Host Third Quarter Ended September 30, 2015 Financial Results Conference Call and Webcast - [GlobeNewswire] - SAN DIEGO and TORONTO -- Aptose Biosciences Inc. (Aptose) (NASDAQ:APTO) , a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, ...
10/15/15 04:00 PMAptose Biosciences to Present at the 2015 BIO Investor Forum - [GlobeNewswire] - SAN DIEGO and TORONTO -- Aptose Biosciences Inc. (NASDAQ:APTO) , a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced ...
08/10/15 08:30 AMNew Strong Buy Stocks for August 10th - Tale of the Tape -
06/10/15 04:00 PMAptose Biosciences announces results of annual and special meeting of shareholders - [CNW Group] - Aptose Biosciences announces results of annual and special meeting of shareholders
06/02/15 01:00 PMAptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia - [CNW Group] - Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia
05/05/15 03:15 PMAptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 - [CNW Group] - Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015
About Aptose Biosciences

Aptose Biosciences logoAptose Biosciences Inc. (Aptose) is a clinical stage biotechnology company. The Company is engaged in development of targeted therapies addressing unmet medical needs in oncology. The Company has product candidates in two classes of anti-cancer therapies: Small molecule program and large molecule program. The Company's group of small molecule compounds includes lead drug APTO-253 in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and other hematologic malignancies. APTO-253 is an inducer of the Kruppel-like factor 4 gene (the Klf4 Gene) for patients with advanced hematologic malignancies. Additionally, the Company has a preclinical small molecule program, APTO-500, targeting maternal embryonic leucine zipper kinase (MELK) for the treatment of various cancers. The Company's large molecule program includes a molecule to target specific cell-surface receptors expressed in certain cancers expressing the Interleukin-17E receptor (IL-17ER).

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: APTO
  • CUSIP:
Key Metrics:
  • Previous Close: $2.44
  • 50 Day Moving Average: $2.68
  • 200 Day Moving Average: $2.64
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $28.10M
  • Current Quarter EPS Consensus Estimate: $-1.49 EPS
Additional Links:
Aptose Biosciences (NASDAQ:APTO) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha